Request a Quote
Events
- Don’t Miss Our Presentation and Booth at BioJapan 2023! | September 26, 2023
- Meet Us at Our Booth in JCA2023! | August 24, 2023
- Webinar: Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform | August 04, 2023
- Join us at the 11th Annual Immuno-Oncology Summit: Aug 7-9 | August 01, 2023
- Join us at Basic Cardiovascular Sciences Scientific Sessions 2023: July 31–August 3 | July 25, 2023
- Meet us at BIO Asia-Taiwan! | July 19, 2023
News
- Biocytogen Officially Launches RenMice® Series | September 15, 2023
- Sep 2023 Newsletter | September 07, 2023
- Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development | September 07, 2023
- Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D | August 30, 2023
- Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies | August 30, 2023
- Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth | August 17, 2023
